« Back to Record
Citation APA

Chiritescu, G., Dumon, K., Mercade, T. M., Lang, I., Vivas, C. S., Papai, Z., Janssens, J., Hendrickx, K., Pracht, M., Van Den Eynde, M., Taieb, J., Moons, V., Geboes, K., Van Laethem, J.-L., Greil, R., Cervantes, A., Vergauwe, P., Ferrante, M., Vanderstraeten, E., Fridrik, M., Wöll, E., Limón, M. L. M., Rivera, F., Sagaert, X., Tejpar, S., & Van Cutsem, E. (2018). A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 29, v105. doi:10.1093/annonc/mdy149.014


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/307318

Chiritescu, G., Dumon, K., Mercade, T. M., Lang, I., Vivas, C. S., Papai, Z., Janssens, J., Hendrickx, K., Pracht, M., Van Den Eynde, M., Taieb, J., Moons, V., Geboes, K., Van Laethem, J.-L., Greil, R., Cervantes, A., Vergauwe, P., Ferrante, M., Vanderstraeten, E., Fridrik, M., Wöll, E., Limón, M. L. M., Rivera, F., Sagaert, X., Tejpar, S., & Van Cutsem, E. (2018). A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 29, v105. doi:10.1093/annonc/mdy149.014